SRR6013594
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- INTERFERON_GAMMA_RESPONSE+0.480
- ALLOGRAFT_REJECTION+0.460
- MYC_TARGETS_V1+0.210
- DNA_REPAIR+0.180
- E2F_TARGETS+0.180
- G2M_CHECKPOINT+0.130
- MYC_TARGETS_V2+0.120
- IL6_JAK_STAT3_SIGNALING+0.090
- IL2_STAT5_SIGNALING+0.080
Top 10 suppressed
- ANGIOGENESIS-0.470
- GLYCOLYSIS-0.450
- CHOLESTEROL_HOMEOSTASIS-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- ESTROGEN_RESPONSE_LATE-0.420
- ESTROGEN_RESPONSE_EARLY-0.400
- HYPOXIA-0.350
- COAGULATION-0.310
- MYOGENESIS-0.300
- MTORC1_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG53 | — | — | 0.874 |
| 2 | HNT34_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.867 |
| 3 | SRR5088834 | — | — | 0.857 |
| 4 | MBCProject_1542_T2_RNA | — | D | 0.855 |
| 5 | NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.841 |
| 6 | SRR8518222 | — | D | 0.835 |
| 7 | C3N-00497 | — | cohortSQ1 | 0.833 |
| 8 | TCGA-CR-6487-01A-11R-1873-07 | — | — | 0.826 |
| 9 | SRR8613734 | — | D | 0.820 |
| 10 | MNG876 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |